{"id":"https://openalex.org/W2017337653","doi":"https://doi.org/10.1159/000139531","title":"The NMDA Receptor Competitive Antagonist CPP Modulates Benzodiazepine Tolerance and Discontinuation","display_name":"The NMDA Receptor Competitive Antagonist CPP Modulates Benzodiazepine Tolerance and Discontinuation","alternate_titles":[],"publication_year":2008,"publication_date":"2008-06-10","ids":{"openalex":"https://openalex.org/W2017337653","doi":"https://doi.org/10.1159/000139531","mag":"2017337653","pmid":"https://pubmed.ncbi.nlm.nih.gov/9399331"},"language":"en","primary_location":{"id":"doi:10.1159/000139531","doi":"https://doi.org/10.1159/000139531","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000139531","pdf_url":null,"source":{"id":"https://openalex.org/S106137443","display_name":"Pharmacology","issn_l":"0031-7012","issn":["0031-7012","1423-0313"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2017337653"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5084011419","display_name":"Jonathan M. Koff","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121934306","display_name":"Tufts University","ror":"https://ror.org/05wvpxv85","country_code":"US","type":"education","lineage":["https://openalex.org/I121934306"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jonathan M. Koff","raw_affiliation_strings":["Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Mass. 02111, USA","Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Mass., USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Mass. 02111, USA","institution_ids":["https://openalex.org/I121934306"]},{"raw_affiliation_string":"Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Mass., USA","institution_ids":["https://openalex.org/I121934306"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072778588","display_name":"Gary A. Pritchard","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I121934306","display_name":"Tufts University","ror":"https://ror.org/05wvpxv85","country_code":"US","type":"education","lineage":["https://openalex.org/I121934306"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gary A. Pritchard","raw_affiliation_strings":["Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Mass., USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Mass., USA","institution_ids":["https://openalex.org/I121934306"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087737186","display_name":"David J. Greenblatt","orcid":"https://orcid.org/0000-0003-4719-6226","observed_orcids":["https://orcid.org/0000-0003-4719-6226"]},"institutions":[{"id":"https://openalex.org/I121934306","display_name":"Tufts University","ror":"https://ror.org/05wvpxv85","country_code":"US","type":"education","lineage":["https://openalex.org/I121934306"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"David J. Greenblatt","raw_affiliation_strings":["Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Mass., USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, Mass., USA","institution_ids":["https://openalex.org/I121934306"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103717606","display_name":"Lawrence G. Miller","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Lawrence G. Miller","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.4602,"has_fulltext":false,"cited_by_count":34,"citation_normalized_percentile":{"value":0.55040163,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":95},"biblio":{"volume":"55","issue":"5","first_page":"217","last_page":"227"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.9520999789237976,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.9520999789237976,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.03240000084042549,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.0031999999191612005,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/benzodiazepine-tolerance","display_name":"benzodiazepine tolerance","score":0.8930000066757202},{"id":"https://openalex.org/keywords/benzodiazepine-discontinuation","display_name":"benzodiazepine discontinuation","score":0.9010000228881836},{"id":"https://openalex.org/keywords/nmda-receptor-antagonist","display_name":"NMDA receptor antagonists","score":0.8080000281333923},{"id":"https://openalex.org/keywords/cpp","display_name":"CPP","score":0.7799999713897705},{"id":"https://openalex.org/keywords/lorazepam","display_name":"lorazepam","score":0.8180000185966492},{"id":"https://openalex.org/keywords/glutamatergic-system","display_name":"glutamatergic system","score":0.9599999785423279},{"id":"https://openalex.org/keywords/seizure-threshold","display_name":"seizure threshold","score":0.6959999799728394},{"id":"https://openalex.org/keywords/benzodiazepine-receptor-binding","display_name":"benzodiazepine binding","score":0.9229999780654907},{"id":"https://openalex.org/keywords/benzodiazepine-withdrawal","display_name":"benzodiazepine withdrawal","score":0.8659999966621399},{"id":"https://openalex.org/keywords/pentylenetetrazole-induced-seizures","display_name":"pentylenetetrazole-induced seizures","score":0.8730000257492065},{"id":"https://openalex.org/keywords/cerebral-cortex","display_name":"cerebral cortex","score":0.7310000061988831}],"concepts":[{"id":"https://openalex.org/C2779706987","wikidata":"https://www.wikidata.org/wiki/Q408265","display_name":"Lorazepam","level":2,"score":0.9067914485931396},{"id":"https://openalex.org/C2778173252","wikidata":"https://www.wikidata.org/wiki/Q83871","display_name":"Benzodiazepine","level":3,"score":0.8272833824157715},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.7348587512969971},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6715447902679443},{"id":"https://openalex.org/C2780648746","wikidata":"https://www.wikidata.org/wiki/Q28208871","display_name":"Glutamatergic","level":4,"score":0.6343714594841003},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.5853245258331299},{"id":"https://openalex.org/C67018056","wikidata":"https://www.wikidata.org/wiki/Q414896","display_name":"NMDA receptor","level":3,"score":0.544338047504425},{"id":"https://openalex.org/C2777836312","wikidata":"https://www.wikidata.org/wiki/Q4386371","display_name":"Dizocilpine","level":4,"score":0.5135607719421387},{"id":"https://openalex.org/C2776175493","wikidata":"https://www.wikidata.org/wiki/Q210402","display_name":"Diazepam","level":2,"score":0.4855777621269226},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4727122485637665},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.47194284200668335},{"id":"https://openalex.org/C168258287","wikidata":"https://www.wikidata.org/wiki/Q60147","display_name":"GABAA receptor","level":3,"score":0.441506028175354},{"id":"https://openalex.org/C2775858608","wikidata":"https://www.wikidata.org/wiki/Q576618","display_name":"Anticonvulsant","level":3,"score":0.42970046401023865},{"id":"https://openalex.org/C2778122271","wikidata":"https://www.wikidata.org/wiki/Q410943","display_name":"Receptor antagonist","level":4,"score":0.4165840744972229},{"id":"https://openalex.org/C2778460930","wikidata":"https://www.wikidata.org/wiki/Q7447053","display_name":"Seizure threshold","level":4,"score":0.4131506383419037},{"id":"https://openalex.org/C61174792","wikidata":"https://www.wikidata.org/wiki/Q420510","display_name":"Glutamate receptor","level":3,"score":0.21908530592918396},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.20728912949562073},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.1923966109752655},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.11699214577674866},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002540","descriptor_name":"Cerebral Cortex","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004361","descriptor_name":"Drug Tolerance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006624","descriptor_name":"Hippocampus","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008140","descriptor_name":"Lorazepam","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D008140","descriptor_name":"Lorazepam","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D008140","descriptor_name":"Lorazepam","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009043","descriptor_name":"Motor Activity","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D010433","descriptor_name":"Pentylenetetrazole","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011963","descriptor_name":"Receptors, GABA-A","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D012640","descriptor_name":"Seizures","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D012640","descriptor_name":"Seizures","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D013375","descriptor_name":"Substance Withdrawal Syndrome","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":true},{"descriptor_ui":"D016194","descriptor_name":"Receptors, N-Methyl-D-Aspartate","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D018691","descriptor_name":"Excitatory Amino Acid Antagonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018691","descriptor_name":"Excitatory Amino Acid Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1159/000139531","doi":"https://doi.org/10.1159/000139531","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000139531","pdf_url":null,"source":{"id":"https://openalex.org/S106137443","display_name":"Pharmacology","issn_l":"0031-7012","issn":["0031-7012","1423-0313"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology","raw_type":"journal-article"},{"id":"pmid:9399331","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9399331","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.5683000087738037,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G2086807074","display_name":null,"funder_award_id":"MH 34223","funder_id":"https://openalex.org/F4320337346","funder_display_name":"National Institute of Mental Health"},{"id":"https://openalex.org/G5001870525","display_name":"PSYCHOTROPIC DRUG SENSITIVITY IN THE ELDERLY","funder_award_id":"R01MH047598","funder_id":"https://openalex.org/F4320337346","funder_display_name":"National Institute of Mental Health"},{"id":"https://openalex.org/G806220931","display_name":null,"funder_award_id":"DA05258","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"}],"funders":[{"id":"https://openalex.org/F4320337346","display_name":"National Institute of Mental Health","ror":"https://ror.org/04xeg9z08"},{"id":"https://openalex.org/F4320337347","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2066874556","https://openalex.org/W2077885190","https://openalex.org/W2008263429","https://openalex.org/W2328168816","https://openalex.org/W1990584558","https://openalex.org/W1997210135","https://openalex.org/W2139738030","https://openalex.org/W1980859538","https://openalex.org/W2243793709","https://openalex.org/W2088095686"],"abstract_inverted_index":{"Benzodiazepine":[0,145],"discontinuation":[1,123],"is":[2,15],"characterized":[3],"by":[4,20,102,131,138,199,206],"a":[5],"syndrome":[6],"of":[7,28,47,95,124,133,166,201,219],"increased":[8,178],"activity":[9],"and":[10,35,44,59,66,71,85,137,164,181,188,226],"reduced":[11,153],"seizure":[12,62,116],"threshold":[13,117],"that":[14],"similar":[16],"to":[17,54,91],"effects":[18,94],"mediated":[19],"the":[21,26,29,40,45,92,142,192,210,217,220],"glutamatergic":[22,30,221],"system.":[23],"To":[24],"elucidate":[25],"involvement":[27,218],"system":[31,222],"in":[32,115,147,223],"benzodiazepine":[33,67,224],"tolerance":[34,81,87,225],"discontinuation,":[36,175],"we":[37],"administered":[38],"lorazepam,":[39],"NMDA":[41],"antagonist":[42],"CPP,":[43],"combination":[46,108],"these":[48],"compounds":[49],"either":[50],"concomitantly":[51],"or":[52],"consecutively":[53],"mice":[55],"via":[56],"osmotic":[57],"pumps":[58],"evaluated":[60],"pentylenetetrazole-induced":[61],"threshold,":[63],"open-field":[64],"activity,":[65],"receptor":[68],"binding":[69,146,176],"during":[70,141,157,209],"after":[72,122],"chronic":[73,158],"administration.":[74],"Animals":[75],"receiving":[76],"lorazepam":[77,125,136,159,174,211],"alone":[78],"developed":[79],"partial":[80,111],"at":[82,88,154,179],"7":[83,182],"days":[84,90,121,156,183],"complete":[86],"14":[89,155],"anticonvulsant":[93],"lorazepam.":[96,106],"This":[97,107,127,195],"effect":[98,128,196],"was":[99,118,129,151,177,197],"partly":[100],"attenuated":[101],"CPP":[103,134,139,167,202,207],"coadministration":[104,132,165,200],"with":[105,135],"produced":[109],"only":[110],"tolerance.":[112],"A":[113],"reduction":[114],"observed":[119],"4":[120,180],"alone.":[126],"abolished":[130,198],"administration":[140,160,208],"withdrawal":[143,212],"period.":[144,213],"most":[148],"structures":[149],"examined":[150],"significantly":[152],"(versus":[161],"1":[162],"day),":[163],"did":[168],"not":[169],"alter":[170],"this":[171],"decrement.":[172],"After":[173],"versus":[184,189],"chronically":[185],"treated":[186],"animals":[187],"vehicle":[190],"within":[191],"cerebral":[193],"cortex.":[194],"as":[203,205],"well":[204],"These":[214],"data":[215],"support":[216],"discontinuation.":[227]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2017337653","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
